Published in FEBS Lett on March 12, 2011
Epigenetic mechanisms in anti-cancer actions of bioactive food components--the implications in cancer prevention. Br J Pharmacol (2012) 1.03
Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives. Curr Pharm Des (2013) 0.91
Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC. Epigenetics (2013) 0.89
Ovarian cancer: in search of better marker systems based on DNA repair defects. Int J Mol Sci (2013) 0.87
Increased DNA methyltransferase activity and DNA methylation following Epidermal Growth Factor stimulation in ovarian cancer cells. Epigenetics (2012) 0.87
Pathway modulations and epigenetic alterations in ovarian tumorbiogenesis. J Cell Physiol (2014) 0.84
Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy. J Cell Mol Med (2016) 0.81
Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation. Epigenetics (2014) 0.80
Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer. J Ovarian Res (2016) 0.78
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
Translating the histone code. Science (2001) 56.77
The language of covalent histone modifications. Nature (2000) 44.92
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet (2004) 37.83
Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A (2008) 33.65
The epigenomics of cancer. Cell (2007) 30.91
MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med (2005) 29.65
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 26.32
A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med (2005) 26.02
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 24.75
Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell (2006) 23.59
Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol (2008) 19.86
Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res (2006) 17.42
Epigenetics in cancer. N Engl J Med (2008) 17.36
MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods (2007) 13.94
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med (1996) 13.49
Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat Rev Genet (2004) 12.97
Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer (2004) 10.31
Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol (2008) 10.28
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol (2002) 9.83
Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark. Mol Cell (2007) 9.73
The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet (2009) 9.68
Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med (2008) 8.77
Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem (2007) 7.49
Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell (2006) 7.33
The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol (2010) 7.27
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol (2008) 6.81
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol (2002) 6.51
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst (2000) 6.38
miR2Disease: a manually curated database for microRNA deregulation in human disease. Nucleic Acids Res (2008) 6.30
Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer (2010) 6.27
Regulation of histone methylation by demethylimination and demethylation. Nat Rev Mol Cell Biol (2007) 6.13
Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov (2010) 6.07
Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res (2007) 5.62
MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res (2008) 5.54
Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA (2007) 5.35
Emerging molecular markers of cancer. Nat Rev Cancer (2002) 5.03
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol (1996) 4.99
Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol (2005) 4.98
RAKE and LNA-ISH reveal microRNA expression and localization in archival human brain. RNA (2005) 4.91
Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotechnol (2007) 4.40
Suppression of intestinal neoplasia by DNA hypomethylation. Cell (1995) 4.16
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res (2006) 4.15
The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol (2008) 4.10
Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat Commun (2011) 4.07
Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol (2007) 4.06
Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med (2003) 4.04
CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene (2007) 3.96
Improved survival in women with BRCA-associated ovarian carcinoma. Cancer (2003) 3.96
The cell of origin of ovarian epithelial tumours. Lancet Oncol (2008) 3.74
Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA (2000) 3.69
Up-regulation of dicer, a component of the MicroRNA machinery, in prostate adenocarcinoma. Am J Pathol (2006) 3.30
Methylation profiling of CpG islands in human breast cancer cells. Hum Mol Genet (1999) 3.26
Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ (2006) 3.12
MicroRNAs 221 and 222 bypass quiescence and compromise cell survival. Cancer Res (2008) 2.97
Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer (2010) 2.95
Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res (2005) 2.92
Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res (2005) 2.86
MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One (2008) 2.60
The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res (2007) 2.54
Clinical practice. Screening for ovarian cancer. N Engl J Med (2009) 2.50
Targeting DNA methylation. Clin Cancer Res (2009) 2.45
Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One (2009) 2.37
MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res (2008) 2.35
RNASEN regulates cell proliferation and affects survival in esophageal cancer patients. Clin Cancer Res (2006) 2.21
Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol (2000) 2.21
CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res (2005) 2.11
Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene (1999) 2.09
Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease? Gene Ther (2006) 2.07
Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res (2003) 2.04
Small-molecule inhibitors of microrna miR-21 function. Angew Chem Int Ed Engl (2008) 2.00
Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell Cycle (2006) 1.98
Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res (2002) 1.91
Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst (2002) 1.87
BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res (2000) 1.83
OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. Nat Genet (2003) 1.77
Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer (2006) 1.77
DNA hypomethylation and ovarian cancer biology. Cancer Res (2004) 1.75
The importance of imprinting in the human placenta. PLoS Genet (2010) 1.74
Complete genetic suppression of polyp formation and reduction of CpG-island hypermethylation in Apc(Min/+) Dnmt1-hypomorphic Mice. Cancer Res (2002) 1.73
Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma. Oncogene (2010) 1.73
MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochim Biophys Acta (2010) 1.69
Retracted Novel approaches for gene-specific interference via manipulating actions of microRNAs: examination on the pacemaker channel genes HCN2 and HCN4. J Cell Physiol (2007) 1.59
Tumorigenesis of chemotherapeutic drug-resistant cancer stem-like cells in brain glioma. Stem Cells Dev (2007) 1.54
Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. Br J Cancer (2010) 1.54
Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res (2006) 1.53
Spheres isolated from 9L gliosarcoma rat cell line possess chemoresistant and aggressive cancer stem-like cells. Stem Cells (2007) 1.53
Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am J Pathol (2001) 1.53
MicroRNAs in ovarian cancer biology and therapy resistance. Int J Biochem Cell Biol (2010) 1.49
Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients. Gynecol Oncol (2009) 1.44
Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biol Ther (2010) 1.37
A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer (2010) 1.34
SGO White Paper on ovarian cancer: etiology, screening and surveillance. Gynecol Oncol (2010) 1.27
Epigenetic therapies for chemoresensitization of epithelial ovarian cancer. Gynecol Oncol (2009) 1.26
Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther (2007) 1.25
Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer (2006) 1.24
Promoter hypermethylation profile of kidney cancer. Clin Cancer Res (2004) 2.02
Global reactivation of epigenetically silenced genes in prostate cancer. Cancer Prev Res (Phila) (2010) 1.66
Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res (2004) 1.66
Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clin Cancer Res (2004) 1.62
Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. Cancer Res (2003) 1.59
Signaling pathways in renal cell carcinoma. Cancer Biol Ther (2010) 1.58
Identification of novel target genes by an epigenetic reactivation screen of renal cancer. Cancer Res (2006) 1.49
Telomerase is frequently activated in tumors with microsatellite instability. Cancer Biol Ther (2004) 1.47
Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation. Clin Cancer Res (2004) 1.31
Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescence. Cancer Res (2011) 1.29
Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res (2004) 1.22
Towards Clinical Application of Methylated DNA Sequences as Cancer Biomarkers: A Joint NCI's EDRN and NIST Workshop on Standards, Methods, Assays, Reagents and Tools. Cancer Res (2007) 1.21
Promoter methylation and the detection of breast cancer. Cancer Causes Control (2009) 1.18
Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Cancer Res (2003) 1.13
Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer. Cancer Res (2008) 1.11
LOT1 (PLAGL1/ZAC1), the candidate tumor suppressor gene at chromosome 6q24-25, is epigenetically regulated in cancer. J Biol Chem (2002) 1.10
Reduction of Pax9 gene dosage in an allelic series of mouse mutants causes hypodontia and oligodontia. Hum Mol Genet (2005) 1.09
ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approaches. Cancer Prev Res (Phila) (2011) 1.03
VILIP-1 downregulation in non-small cell lung carcinomas: mechanisms and prediction of survival. PLoS One (2008) 1.00
Reducing number entry errors: solving a widespread, serious problem. J R Soc Interface (2010) 1.00
DNA methylation in pre-diagnostic serum samples of breast cancer cases: results of a nested case-control study. Cancer Epidemiol (2010) 0.98
The genetics of renal oncocytosis: a possible model for neoplastic progression. Cancer Genet Cytogenet (2004) 0.93
The effect of interruptions on postcompletion and other procedural errors: an account based on the activation-based goal memory model. J Exp Psychol Appl (2008) 0.92
Epigenetics of kidney cancer and bladder cancer. Epigenomics (2011) 0.91
Assays for hypermethylation of the BRCA1 gene promoter in tumor cells to predict sensitivity to PARP-inhibitor therapy. Methods Mol Biol (2011) 0.89
Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC. Epigenetics (2013) 0.89
Haploinsufficiency of the germ cell-specific nuclear RNA binding protein hnRNP G-T prevents functional spermatogenesis in the mouse. Hum Mol Genet (2008) 0.86
Induction of the estrogen receptor by ablation of DNMT1 in ER-negative breast cancer cells. Cancer Biol Ther (2003) 0.84
Molecular genetics and histopathologic features of adult distal nephron tumors. Urology (2002) 0.82
The basic biology and immunobiology of renal cell carcinoma: considerations for the clinician. Urol Clin North Am (2003) 0.81
Evaluating care pathways for community psychiatry in England: a qualitative study. J Eval Clin Pract (2012) 0.81
Genome-wide promoter methylome of small renal masses. PLoS One (2013) 0.80
Epigenomics-based diagnostics. Clin Chem (2010) 0.79
Characterization of starch from tubers of yam bean (Pachyrhizus ahipa). J Agric Food Chem (2002) 0.77
Synergistic interactions between the genetically modified bacterial polysaccharide P2 and carob or konjac mannan. Carbohydr Res (2004) 0.75